Patents by Inventor Aaron D. Schuler

Aaron D. Schuler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating cancer using chemokine antagonists
    Patent number: 10993953
    Abstract: What is described is a method for treating cancer in a patient assaying levels of (a) CXCR1 and/or CXCR2 ligands or (b) myeloid derived suppressor cells (MDSCs) and/or neutrophils in the patient, and if the patient has increased levels of (a) or (b), then administering a therapeutically effective amount of a compound having a structure selected from the group consisting of formulas SX-517, SX-576, and SX-682
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: May 4, 2021
    Assignee: Syntrix Biosystems Inc.
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Method for treating cancer using chemokine antagonists
    Patent number: 10660909
    Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 26, 2020
    Assignee: Syntrix Biosystems Inc.
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS
    Publication number: 20190381076
    Abstract: What is described is a method for treating cancer in a patient assaying levels of (a) CXCR1 and/or CXCR2 ligands or (b) myeloid derived suppressor cells (MDSCs) and/or neutrophils in the patient, and if the patient has increased levels of (a) or (b), then administering a therapeutically effective amount of a compound having a structure selected from the group consisting of formulas SX-517, SX-576, and SX-682
    Type: Application
    Filed: August 26, 2019
    Publication date: December 19, 2019
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Use of thiopyrimidinecarboxamide for treating cancer
    Patent number: 10130645
    Abstract: There is disclosed is a method of treating disease using compound having formula SX-682 alone or in combination with an antineoplastic agent, microtubule affecting agents, antineoplastic agents, anti-angiogenesis agents, VEGF receptor kinase inhibitors, antibodies against the VEGF receptor, interferon, or radiation.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: November 20, 2018
    Assignee: Syntrix Biosystems, Inc.
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • METHOD FOR TREATING CANCER USING DUAL ANTAGONISTS OF CXCR1 AND CXCR2
    Publication number: 20180296580
    Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of a dual CXCR1/2 antagonist by administering a therapeutically effective amount of a dual CXCR1/2 antagonist, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
    Type: Application
    Filed: June 25, 2018
    Publication date: October 18, 2018
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Method for treating cancer using chemokine antagonists
    Patent number: 10046002
    Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: August 14, 2018
    Assignee: SYNTRIX BIOSYSTEMS INC.
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS
    Publication number: 20180177808
    Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
    Type: Application
    Filed: February 23, 2018
    Publication date: June 28, 2018
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • USE OF THIOPYRIMIDINECARBOXAMIDE FOR TREATING CANCER
    Publication number: 20170281659
    Abstract: There is disclosed is a method of treating disease using compound having formula SX-682 alone or in combination with an antineoplastic agent, microtubule affecting agents, antineoplastic agents, anti-angiogenesis agents, VEGF receptor kinase inhibitors, antibodies against the VEGF receptor, interferon, or radiation.
    Type: Application
    Filed: June 20, 2017
    Publication date: October 5, 2017
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Use of thiopyrimidinecarboxamide for treating cancer
    Patent number: 9707248
    Abstract: There is disclosed is a method of treating cancer using compound having formula SX-682 alone or in combination with an antineoplastic agent, microtubule affecting agents, antineoplastic agents, anti-angiogenesis agents, VEGF receptor kinase inhibitors, antibodies against the VEGF receptor, interferon, or radiation.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: July 18, 2017
    Assignee: Syntrix Biosystems Inc.
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS
    Publication number: 20170128474
    Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
    Type: Application
    Filed: November 17, 2016
    Publication date: May 11, 2017
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • USE OF THIOPYRIMIDINECARBOXAMIDE FOR TREATING CANCER
    Publication number: 20170014435
    Abstract: There is disclosed is a method of treating cancer using compound having formula SX-682 alone or in combination with an antineoplastic agent, microtubule affecting agents, antineoplastic agents, anti-angiogenesis agents, VEGF receptor kinase inhibitors, antibodies against the VEGF receptor, interferon, or radiation.
    Type: Application
    Filed: September 28, 2016
    Publication date: January 19, 2017
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Thiopyrimidinecarboxamide for use in treating pulmonary disease
    Patent number: 9480694
    Abstract: There is disclosed is a method of treating a pulmonary disease using a pyrimidinecarboxamide compound, and a pharmaceutical composition suitable for inhalation comprising the pyrimidinecarboxamide compound.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: November 1, 2016
    Assignee: Syntrix Biosystems, Inc.
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • THIOPYRIMIDINECARBOXAMIDES AS CXCR1/2 MODULATORS
    Publication number: 20150147341
    Abstract: There is disclosed is a method of treating a pulmonary disease using a pyrimidinecarboxamide compound, and a pharmaceutical composition suitable for inhalation comprising the pyrimidinecarboxamide compound.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 28, 2015
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Aminopyrimidinecarboxamides as CXCR2 modulators
    Patent number: 8993541
    Abstract: There are disclosed aminopyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include aminopyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: March 31, 2015
    Assignee: Syntrix Biosystems, Inc.
    Inventors: Dean Y. Maeda, John A. Zebala, Aaron D. Schuler
  • Thiopyrimidinecarboxamides as CXCR1/2 modulators
    Patent number: 8969365
    Abstract: There is disclosed a pyrimidinecarboxamide compound useful as a pharmaceutical agent, synthetic processes, and pharmaceutical compositions which include the pyrimidinecarboxamide compound. More specifically, there is disclosed a CXCR1/2 inhibitor useful for treating a variety of inflammatory and neoplastic disorders.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: March 3, 2015
    Assignee: Syntrix Biosystems, Inc.
    Inventors: Dean Y. Maeda, John A. Zebala, Aaron D. Schuler
  • THIOPYRIMIDINECARBOXAMIDES AS CXCR1/2 MODULATORS
    Publication number: 20150038461
    Abstract: There is disclosed a pyrimidinecarboxamide compound useful as a pharmaceutical agent, synthetic processes, and pharmaceutical compositions which include the pyrimidinecarboxamide compound. More specifically, there is disclosed a CXCR1/2 inhibitor useful for treating a variety of inflammatory and neoplastic disorders.
    Type: Application
    Filed: August 2, 2013
    Publication date: February 5, 2015
    Applicant: Syntrix Biosystems, Inc.
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Aminopyrimidinecarboxamides as CXCR2 Modulators
    Publication number: 20140256678
    Abstract: There are disclosed aminopyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include aminopyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.
    Type: Application
    Filed: May 20, 2014
    Publication date: September 11, 2014
    Applicant: Syntrix Biosystems, Inc.
    Inventors: Dean Y. Maeda, John A. Zebala, Aaron D. Schuler
  • Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
    Patent number: 8779149
    Abstract: There is disclosed aminopyridine- and aminopyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include aminopyridine- and aminopyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: July 15, 2014
    Assignee: Syntrix Biosystems, Inc.
    Inventors: Dean Y. Maeda, John A. Zebala, Aaron D. Schuler
  • Aminopyridinecarboxamides as CXCR2 modulators
    Patent number: RE47740
    Abstract: There is disclosed aminopyridine- and aminopyrimidinecarboxamide aminopyridinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include aminopyridine- and aminopyrimidinecarboxamides aminopyridinecarboxamide compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: November 26, 2019
    Assignee: Syntrix Biosystems Inc.
    Inventors: Dean Y. Maeda, John A. Zebala, Aaron D. Schuler
  • Aminopyrimidinecarboxamides as CXCR2 modulators
    Patent number: RE48547
    Abstract: There are disclosed aminopyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include aminopyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: May 11, 2021
    Assignee: Syntrix Biosystems Inc.
    Inventors: Dean Y. Maeda, John A. Zebala, Aaron D. Schuler